This webinar aims to provide a comprehensive review of the latest updates in DATA Waiver and DEA Training prerequisites for medication-assisted treatment (MAT) and buprenorphine. It will explore the reasons behind the implementation of the Waiver Elimination (MAT-Act), outline the key components of the MAT-Act that took effect in 2023, highlight the advantages of the MAT-Act for healthcare providers and prescribers, and inform participants about the free training and consultation opportunities related to the treatment of patients with Opioid Use Disorder (MOUD).

Thursday, January 18
1:00-1:30 p.m. ET

Learn more and register here.

Earn 0.5 continuing education credits for attending this session.